Literature DB >> 27483339

Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model.

Maaike Everts1, Tomas Cihlar2, J Robert Bostwick3, Richard J Whitley1.   

Abstract

Drug discovery and development is a lengthy and expensive process. Although no one, simple, single solution can significantly accelerate this process, steps can be taken to avoid unnecessary delays. Using the development of antiviral therapies as a model, we describe options for acceleration that cover target selection, assay development and high-throughput screening, hit confirmation, lead identification and development, animal model evaluations, toxicity studies, regulatory issues, and the general drug discovery and development infrastructure. Together, these steps could result in accelerated timelines for bringing antiviral therapies to market so they can treat emerging infections and reduce human suffering.

Entities:  

Keywords:  antivirals; drug discovery; emerging infections

Mesh:

Substances:

Year:  2016        PMID: 27483339     DOI: 10.1146/annurev-pharmtox-010716-104533

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  10 in total

1.  Antiviral activity of shikonin ester derivative PMM-034 against enterovirus 71 in vitro.

Authors:  Y Zhang; H Han; L Sun; H Qiu; H Lin; L Yu; W Zhu; J Qi; R Yang; Y Pang; X Wang; G Lu; Y Yang
Journal:  Braz J Med Biol Res       Date:  2017-08-17       Impact factor: 2.590

2.  In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies.

Authors:  Chasity D Andrews; Yaoxing Huang; David D Ho; Rachel A Liberatore
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

3.  Highlights of the 30th International Conference on Antiviral Research.

Authors:  Graciela Andrei; Kara Carter; Zlatko Janeba; Aruna Sampath; Luis M Schang; E Bart Tarbet; R Anthony Vere Hodge; Mike Bray; José A Esté
Journal:  Antiviral Res       Date:  2017-08-01       Impact factor: 5.970

Review 4.  Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.

Authors:  Rolando Cannalire; Carmen Cerchia; Andrea R Beccari; Francesco Saverio Di Leva; Vincenzo Summa
Journal:  J Med Chem       Date:  2020-11-13       Impact factor: 7.446

Review 5.  The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents.

Authors:  Gustavo R Villas-Boas; Vanessa C Rescia; Marina M Paes; Stefânia N Lavorato; Manoel F de Magalhães-Filho; Mila S Cunha; Rafael da C Simões; Roseli B de Lacerda; Renilson S de Freitas-Júnior; Bruno H da S Ramos; Ana M Mapeli; Matheus da S T Henriques; William R de Freitas; Luiz A F Lopes; Luiz G R Oliveira; Jonatas G da Silva; Saulo E Silva-Filho; Ana P S da Silveira; Katyuscya V Leão; Maria M de S Matos; Jamille S Fernandes; Roberto K N Cuman; Francielli M de S Silva-Comar; Jurandir F Comar; Luana do A Brasileiro; Jussileide N Dos Santos; Silvia A Oesterreich
Journal:  Molecules       Date:  2020-09-07       Impact factor: 4.411

6.  Development of peptides targeting receptor binding site of the envelope glycoprotein to contain the West Nile virus infection.

Authors:  Patrícia Mertinková; Evelína Mochnáčová; Katarína Bhide; Amod Kulkarni; Zuzana Tkáčová; Jana Hruškovicová; Mangesh Bhide
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

7.  Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.

Authors:  Matthew D Hall; James M Anderson; Annaliesa Anderson; David Baker; Jay Bradner; Kyle R Brimacombe; Elizabeth A Campbell; Kizzmekia S Corbett; Kara Carter; Sara Cherry; Lillian Chiang; Tomas Cihlar; Emmie de Wit; Mark Denison; Matthew Disney; Courtney V Fletcher; Stephanie L Ford-Scheimer; Matthias Götte; Abigail C Grossman; Frederick G Hayden; Daria J Hazuda; Charlotte A Lanteri; Hilary Marston; Andrew D Mesecar; Stephanie Moore; Jennifer O Nwankwo; Jules O'Rear; George Painter; Kumar Singh Saikatendu; Celia A Schiffer; Timothy P Sheahan; Pei-Yong Shi; Hugh D Smyth; Michael J Sofia; Marla Weetall; Sandra K Weller; Richard Whitley; Anthony S Fauci; Christopher P Austin; Francis S Collins; Anthony J Conley; Mindy I Davis
Journal:  J Infect Dis       Date:  2021-07-15       Impact factor: 7.759

Review 8.  Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.

Authors:  Gaspar Taroncher-Oldenburg; Christin Müller; Wiebke Obermann; John Ziebuhr; Roland K Hartmann; Arnold Grünweller
Journal:  Microorganisms       Date:  2021-03-05

Review 9.  Live unattenuated vaccines for controlling viral diseases, including COVID-19.

Authors:  Ji-Ming Chen
Journal:  J Med Virol       Date:  2020-09-29       Impact factor: 20.693

Review 10.  Improving target assessment in biomedical research: the GOT-IT recommendations.

Authors:  Christoph H Emmerich; Lorena Martinez Gamboa; Martine C J Hofmann; Marc Bonin-Andresen; Olga Arbach; Pascal Schendel; Björn Gerlach; Katja Hempel; Anton Bespalov; Ulrich Dirnagl; Michael J Parnham
Journal:  Nat Rev Drug Discov       Date:  2020-11-16       Impact factor: 112.288

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.